SynAct Pharma AB (“SynAct”) today announced that an abstract entitled ”AP1189: A Novel Oral Biased Melanocortin Agonist with Anti-inflammatory and Pro-resolving Effect for the Treatment of Rheumatoid Arthritis” has been selected for presentation at the ACR Convergence 2021 conference on November 9. AP1189 is a novel oral available compound with anti-inflammatory and pro-resolving effect with the potential to treat active rheumatoid arthritis (RA).
SynAct Pharma will present the compound’s topline pharmacology and efficacy data at the event. The compound is currently being tested in a double-blind placebo-controlled Phase 2a clinical trial in Europe. The primary aim of the study is to evaluate safety and tolerability and potential treatment effects of the compound relative to placebo.
“We are delighted to get the opportunity to present key data related to AP1189 and the potential treatment effects in RA at the ACR Convergence 2021” said SynAct’s CSO Thomas Jonassen.
The information was submitted, through the agency of the contact person below, for publication on August 20, 2021
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen Thomas Jonassen
CEO, SynAct Pharma AB CSO, SynAct Pharma AB
Phone: +45 28 44 75 67 Phone: +45 40 15 66 69
Mail: [email protected] Mail: [email protected]